D.A. Davidson & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.04M | Sell |
8,128
-424
| -5% | -$52.9K | 0.01% | 920 |
|
|
2025
Q4 | $1.04M | Sell |
8,552
-481
| -5% | -$55.1K | 0.01% | 879 |
|
|
2025
Q3 | $905K | Sell |
9,033
-656
| -7% | -$59.1K | 0.01% | 912 |
|
|
2025
Q2 | $804K | Sell |
9,689
-400
| -4% | -$31.9K | 0.01% | 874 |
|
|
2025
Q1 | $818K | Sell |
10,089
-185
| -2% | -$16.5K | 0.01% | 843 |
|
|
2024
Q4 | $925K | Sell |
10,274
-150
| -1% | -$14.5K | 0.01% | 802 |
|
|
2024
Q3 | $1.03M | Sell |
10,424
-20,024
| -66% | -$1.97M | 0.01% | 760 |
|
|
2024
Q2 | $2.82M | Sell |
30,448
-11,914
| -28% | -$1.07M | 0.03% | 442 |
|
|
2024
Q1 | $4.02M | Buy |
42,362
+30,197
| +248% | +$2.8M | 0.04% | 345 |
|
|
2023
Q4 | $1.09M | Sell |
12,165
-2,012
| -14% | -$149K | 0.01% | 688 |
|
|
2023
Q3 | $1.04M | Sell |
14,177
-712
| -5% | -$56.9K | 0.01% | 674 |
|
|
2023
Q2 | $1.24M | Sell |
14,889
-27
| -0.2% | -$2.26K | 0.01% | 623 |
|
|
2023
Q1 | $1.14M | Buy |
14,916
+1,105
| +8% | +$91.7K | 0.01% | 628 |
|
|
2022
Q4 | $1.15M | Buy |
13,811
+410
| +3% | +$33.2K | 0.01% | 587 |
|
|
2022
Q3 | $1.06M | Buy |
13,401
+1,289
| +11% | +$109K | 0.01% | 571 |
|
|
2022
Q2 | $900K | Buy |
12,112
+894
| +8% | +$67.1K | 0.01% | 629 |
|
|
2022
Q1 | $1.01M | Buy |
11,218
+806
| +8% | +$74.4K | 0.01% | 652 |
|
|
2021
Q4 | $1.17M | Buy |
10,412
+886
| +9% | +$107K | 0.01% | 607 |
|
|
2021
Q3 | $1.2M | Buy |
9,526
+491
| +5% | +$63.2K | 0.01% | 575 |
|
|
2021
Q2 | $1.22M | Sell |
9,035
-1,867
| -17% | -$245K | 0.01% | 571 |
|
|
2021
Q1 | $1.48M | Buy |
10,902
+2,277
| +26% | +$341K | 0.02% | 474 |
|
|
2020
Q4 | $1.21M | Buy |
8,625
+148
| +2% | +$19K | 0.02% | 462 |
|
|
2020
Q3 | $945K | Buy |
8,477
+203
| +2% | +$22.8K | 0.02% | 462 |
|
|
2020
Q2 | $926K | Buy |
8,274
+4,113
| +99% | +$405K | 0.02% | 459 |
|
|
2020
Q1 | $322K | Buy |
4,161
+151
| +4% | +$13.4K | 0.01% | 712 |
|
|
2019
Q4 | $381K | Buy |
4,010
+209
| +5% | +$18.1K | 0.01% | 751 |
|
|
2019
Q3 | $290K | Sell |
3,801
-10
| -0.3% | -$831 | 0.01% | 795 |
|
|
2019
Q2 | $334K | Sell |
3,811
-35
| -0.9% | -$2.98K | 0.01% | 744 |
|
|
2019
Q1 | $348K | Sell |
3,846
-50
| -1% | -$4.25K | 0.01% | 807 |
|
|
2018
Q4 | $280K | Sell |
3,896
-80
| -2% | -$6.45K | 0.01% | 843 |
|
|
2018
Q3 | $381K | Buy |
3,976
+86
| +2% | +$8.34K | 0.01% | 815 |
|
|
2018
Q2 | $370K | Buy |
3,890
+115
| +3% | +$10.6K | 0.01% | 803 |
|
|
2018
Q1 | $331K | Sell |
3,775
-380
| -9% | -$34.7K | 0.01% | 832 |
|
|
2017
Q4 | $353K | Sell |
4,155
-275
| -6% | -$23K | 0.01% | 779 |
|
|
2017
Q3 | $383K | Hold |
4,430
| – | – | 0.01% | 753 |
|
|
2017
Q2 | $341K | Buy |
4,430
+1,000
| +29% | +$70.9K | 0.01% | 738 |
|
|
2017
Q1 | $237K | Buy |
3,430
+75
| +2% | +$5.04K | 0.01% | 868 |
|
|
2016
Q4 | $198K | Buy |
+3,355
| New | +$207K | ﹤0.01% | 1010 |
|
Other funds holding XBI
D.A. Davidson & Co's XBI Position: Q1 2026 in Review
D.A. Davidson & Co reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 5% in Q1 2026, selling an estimated $52.9K and leaving 8,128 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #920.
D.A. Davidson & Co first reported a position in XBI in Q4 2016 and has held it in 38 quarters since. The position peaked at $4.02M in Q1 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- D.A. Davidson & Co held 8,128 shares of State Street SPDR S&P Biotech ETF worth $1.04M as of Q1 2026.
- D.A. Davidson & Co sold 424 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $52.9K.
- State Street SPDR S&P Biotech ETF made up 0.01% of D.A. Davidson & Co's portfolio in Q1 2026, its #920 holding.
- D.A. Davidson & Co first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 38 quarters since.
- D.A. Davidson & Co's State Street SPDR S&P Biotech ETF position peaked at $4.02M in Q1 2024.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on D.A. Davidson & Co's 13F filing for Q1 2026, filed 5 May 2026.